

## KEY INCLUSION CRITERIA AIRFLOW-3

- ✓ 40+ years old
- ✓ BMI 18-35
- ✓ 25-80% FEV<sub>1</sub> predicted and FEV<sub>1</sub>/FVC <70% post-bronchodilator
- ✓ 2+ moderate (OCS and/or antibiotics treatment) or 1+ severe (ER or hospitalization) COPD exacerbations in past year
- ✓ CAT ≥10
- ✓ Non-smoking/non-vaping 2+ months
- ✓ Candidate for bronchoscopy and general anesthesia
- ✓ Current flu vaccine (or willingness to be vaccinated once available)
- ✓ Resting SpO<sub>2</sub> ≥89% on room air
- ✓ 4+ weeks since most recent COPD exacerbation

## KEY EXCLUSION CRITERIA AIRFLOW-3

- ✗ Ongoing GI-related symptoms (i.e. severe uncontrolled GERD or severe dysphagia, gastroparesis, or recent major GI surgery)
- ✗ Diagnosis of active non-COPD lung disease
- ✗ Clinically relevant bronchiectasis
- ✗ Current diagnosis of active asthma
- ✗ MI <6 months, EKG evidence of life-threatening arrhythmias or acute ischemia
- ✗ Pre-existing documented LVEF <40%, stage C or D ACC/AHA or Class III or IV (NYHA) CHF
- ✗ Diagnosed pulmonary hypertension with clinical evidence of CV function impairment [peripheral edema, sustained mPAP >25 mmHg at rest (right heart cath) or estimated RVSP >50 mmHg (echo)]
- ✗ Radiation or chemo treatment within 1 year of consent
- ✗ >10 mg daily prednisone or equivalent

**Pulmonary Rehab:** *Not required* for this trial.  
(If in rehab, wait 3 months after completion before consenting)

**Endobronchial Valves:** Patients *may be eligible if* EBV implant >1 year (OR EBV explant >3 months **and** implant >1 year)

**Opioids:** *Low dose use allowed for valid medical condition*

The Nuvaira Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).

MCA-0125.D 0821 AF3 Protocol Rev F  
© 2021 Nuvaira, Inc. All rights reserved.

**NUVAIRA**<sup>®</sup>

# AIRFLOW 3

COPD CLINICAL TRIAL

## PATIENT SCREENING GUIDE

The Nuaira® Lung Denervation System is designed to reduce moderate or severe exacerbations in COPD patients with high symptom burden.

Diagnosed COPD  
FEV<sub>1</sub> 25-80%  
post-bronchodilator



40+ years old  
BMI 18-35



High Symptom  
Burden



COPD Exacerbations  
2+ Moderate OR  
1+ Severe in Past Year



Ex-Smoker  
2+ Months



Dual or Triple Therapy



Current  
Flu Vaccine



Resting SpO<sub>2</sub> ≥89%  
on Room Air



No Uncontrolled  
Gastric Symptoms

